QLT USA Company Description
QLT USA fought cancer one long-acting injection at a time. The company developed Eligard, a treatment for advanced prostate cancer, using its Atrigel sustained-release injection technology. The drug was approved in North America, where it was marketed by Sanofi-Aventis; in Europe, where Astellas Pharma and MediGene shared marketing rights; and in Australia and New Zealand, where Mayne Pharma sold the drug. QLT USA's parent, Canadian drugmaker QLT, divested the unit's topical acne medication Aczone in 2008 as part of its corporate restructuring program to focus on its Visudyne ocular therapy. QLT then sold the remaining operations of QLT USA to TOLMAR Holding (the contract manufacturer for Eilgard) in 2009.
View the Comprehensive Company Description for QLT USA
The Company Description provides a historical perspective of QLT USA's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of QLT USA's evolution in the marketplace.
